Discovery Labs to Report Second Quarter 2013 Results and Hold Conference Call on Thursday, August 8, 2013

Discovery Labs to Report Second Quarter 2013 Results and Hold Conference Call
                         on Thursday, August 8, 2013

PR Newswire

WARRINGTON, Pa., July 25, 2013

WARRINGTON, Pa., July 25, 2013 /PRNewswire/ --Discovery Laboratories, Inc.
(Nasdaq: DSCO) will report second quarter 2013 results on Thursday, August 8,
2013 before the open of the U.S. financial markets. The Company will also
host a conference call at 10:00a.m. ET that same day to discuss the second
quarter financial results and other business updates. A question-and-answer
session will follow managements' remarks.

To access the conference call and participate in the question-and-answer
session, the number for domestic callers is (877) 215-0093 and for
international callers (706) 679-3237. The conference call passcode is
20041973. An audio replay of the conference call will be available until
September 8, 2013. The replay number is (855) 859-2056 or (404) 537-3406
using the same conference call password listed above.

The audio webcast of the conference call will be available on the Discovery
Labs website at www.discoverylabs.com. It is recommended that participants
log onto the audio webcast at least 15 minutes prior to the call. A replay
of the audio webcast will be available for up to 45 days after the call at the
Company's website.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on
advancing a new standard in respiratory critical care. Discovery Labs' novel
proprietary KL4 surfactant technology produces a synthetic, peptide-containing
surfactant that is structurally similar to pulmonary surfactant. Discovery
Labs is also developing its proprietary drug delivery technologies to enable
efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.
Discovery Labs' strategy is initially focused on neonatology and improving the
management of respiratory distress syndrome (RDS) in premature infants.
Discovery Labs believes that its RDS product portfolio has the potential to
become the new standard of care for RDS and, over time, significantly expand
the current worldwide RDS market.

For more information, please visit the Company's website at
www.discoverylabs.com.



SOURCE Discovery Laboratories, Inc.

Website: http://www.discoverylabs.com
Contact: Investor Relations: Michael Rice, LifeSci Advisors - 646.597.6979, or
Company: John Tattory, Vice President, Finance, Discovery Labs - 215.488.9418